12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dulaglutide: Phase III data

Top-line data from the double-blind, international Phase III AWARD-3 trial in 807 patients with early Type II diabetes showed that once-weekly 1.5 mg subcutaneous dulaglutide met the primary endpoint of non-inferiority to metformin in reducing HbA1c from baseline to week 26. Additionally, the trial was designed to assess superiority of both once-weekly 0.75...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >